• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month

    4/15/24 6:31:12 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email

     walgreens (Facebook Post)

    CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation's medically underserved populations, and Foundation for Sarcoidosis Research (FSR), the leading international sarcoidosis organization, are proud to announce its renewed partnership to raise education and awareness about sarcoidosis and the importance of spring vaccinations with all Alabama-based Walgreens stores. As part of April's Sarcoidosis Awareness Month from now through April 30th, all Walgreens stores in Alabama will join forces with FSR in an effort to spread awareness and support those affected by this chronic disease.

    During this awareness campaign, Walgreens stores across Alabama will provide informational resources about sarcoidosis to their customers. Visitors will have the opportunity to learn about the disease and its effects on individuals within their own communities through patient profiles displayed prominently at the registers. Moreover, Walgreens customers visiting Alabama stores will have the chance to contribute to FSR's mission by donating in $1, $5, and $10 increments at checkout registers. Every donation will directly support FSR's initiatives to accelerate sarcoidosis research and provide crucial support to patients and their families.

    Sarcoidosis is a rare inflammatory disease that can impact any organ of the body and often leads to severe chronic illness and even death. To improve diagnosis and clinical treatment, FSR created the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) which is a member program consisting of clinics, hospitals, individual providers, patients, and caregivers committed to finding a cure, providing community education and support, and offering evidence-based, patient-centric care for those living with sarcoidosis. University of Alabama at Birmingham (UAB) Medicine is an FSR-GSCA Founding Member, providing comprehensive, collaborative care for sarcoidosis.

    "This year, more than ever, we are ‘saying sarcoidosis' to raise awareness in healthcare and in the community amongst our partner locations at Walgreens," said Dr. Joseph Barney, UAB Medicine. "It is time for everyone to know who is affected by sarcoidosis and how they can get help."

    90% of those living with sarcoidosis experience lung involvement. FSR is proud to partner with Walgreens to raise awareness of the spring respiratory vaccines, which include RSV and Pneumonia. Respiratory syncytial virus, or RSV, is a common respiratory virus that typically causes mild, cold-like symptoms. Most people recover within two weeks. However, certain groups, such as infants, young children, older adults, and those who are immunocompromised – like those with sarcoidosis – are more likely to develop severe infections including bronchiolitis (an inflammation of the small airways in the lung) and pneumococcal pneumonia. Pneumonia is a lung disease caused by streptococcus pneumoniae bacteria that can infect the upper respiratory tract and spread to the blood, lungs, middle ear or nervous system. Pneumonia leads to over 150,000 hospitalizations and 5,000 deaths annually. This is also a primary concern for those who have complex lung diseases, like sarcoidosis.

    Through the partnership with Walgreens, FSR is taking the opportunity to remind all with lung and heart disease that now is the time to ask your doctor and pharmacist about spring vaccinations, including for RSV and Pneumonia. To learn more about sarcoidosis and spring vaccinations, visit https://www.stopsarcoidosis.org/walgreens-spring-vaccines/.

    "We are thrilled to collaborate with Walgreens once again to shine a spotlight on sarcoidosis, the importance of spring vaccines, and to extend our reach within Alabama communities," said Mary McGowan, Chief Executive Officer at FSR. "Through this partnership, we aim to foster greater understanding of sarcoidosis while raising vital funds to drive research and support initiatives that enhance the lives of those affected by this complex disease."

    About Sarcoidosis

    Sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Despite increasing advances in research, sarcoidosis remains difficult to diagnose with limited treatment options and no known cure.

    About the Foundation for Sarcoidosis Research (FSR)

    The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education, and support. Since its establishment in 2000, FSR has fostered over $6.5 million in sarcoidosis-specific research efforts. For more information and to join our community, visit www.stopsarcoidosis.org.

    About Walgreens

    Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (NASDAQ:WBA), an integrated healthcare, pharmacy and retail leader with a 170-year heritage of caring for communities. WBA's purpose is to create more joyful lives through better health. Operating nearly 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving nearly 10 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation's medically underserved populations. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with fully integrated physical and digital platforms supported by the latest technology to deliver high-quality products.

    Media Contact:

    Cathi Davis

    [email protected]

    A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/e6a71669-59e5-4566-81a2-aadc98f804ba



    Primary Logo

    Get the next $WBA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/15/24 5:45:26 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/2/24 6:40:23 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    SEC Filings

    View All

    SEC Form 8-K filed by Walgreens Boots Alliance Inc.

    8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    7/15/25 4:30:52 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13E3/A filed by Walgreens Boots Alliance Inc.

    SC 13E3/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    7/11/25 4:34:10 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 8-K filed by Walgreens Boots Alliance Inc.

    8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    7/11/25 4:30:33 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:18:27 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Director Graham Ginger L

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:15:35 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Director Babiak Janice M.

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:13:29 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Walgreens Specialty Pharmacy Strengthens Market Position Through Expanded Limited Distribution Network

    Walgreens Specialty Pharmacy network grows manufacturer relationships in limited distribution drug space Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to now include 265 products, placing it among the leading networks in specialty pharmacies. LDDs are specialty medications that are available through select specialty pharmacies chosen by the drug manufacturer and are often medications with complex regimens, high costs and/or require special handling. As the largest independent specialty pharmacy not directly affiliated with a pharmacy benefit manager (PBM), Walgreens Specialty Pharmacy is able to collaborate with any partner. "As the limited distri

    8/19/25 9:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Blazing Star Merger Sub, Inc. announces extension of the expiration time and settlement date for the previously announced Tender Offer and Consent Solicitation for any and all Walgreens Boots Alliance, Inc.'s 3.600% senior notes due 2025, 2.125% senior notes due 2026, 3.450% notes due 2026, 8.125% notes due 2029, 3.200% Notes due 2030, 4.500% senior notes due 2034, 4.800% senior notes due 2044, 4.650% notes due 2046 and 4.100% Notes due 2050, and any and all of Walgreen Co.'s 4.400% notes due 2042

    NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the extension of the Expiration Time and the Settlement Date (as defined below) for (A) the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"), (7) 4.800% sen

    8/18/25 7:04:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Blazing Star Merger Sub, Inc. announces pricing terms for the previously announced Tender Offer and Consent Solicitation for any and all Walgreens Boots Alliance, Inc.'s 3.600% senior notes due 2025, 2.125% senior notes due 2026, 3.450% notes due 2026, 8.125% notes due 2029, 3.200% Notes due 2030, 4.500% senior notes due 2034, 4.800% senior notes due 2044, 4.650% notes due 2046 and 4.100% Notes due 2050, and any and all of Walgreen Co.'s 4.400% notes due 2042

    NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the pricing for the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"), (7) 4.800% senior notes due 2044 (the "2044 Notes"), (8) 4.650% notes due 2046 (the "20

    8/5/25 3:31:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

    2/28/25 7:36:45 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

    Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

    2/26/24 8:28:07 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance downgraded by HSBC Securities

    HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

    2/20/24 10:23:30 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

    Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

    10/7/24 8:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

    Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

    8/16/24 9:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

    NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

    7/12/24 8:00:00 PM ET
    $NDAQ
    $SMCI
    $WBA
    Investment Bankers/Brokers/Service
    Finance
    Computer Manufacturing
    Technology

    $WBA
    Financials

    Live finance-specific insights

    View All

    Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

    Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

    7/11/25 9:59:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

    Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

    6/26/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

    Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

    4/8/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    2/13/24 5:17:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples